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Abstract
Background: Breast-conserving surgery for breast cancer was developed as a method to preserve healthy breast
tissue, thereby improving cosmetic outcomes. Thus far, the primary aim of breast-conserving surgery has been the
achievement of tumour-free resection margins and prevention of local recurrence, whereas the cosmetic outcome
has been considered less important. Large studies have reported poor cosmetic outcomes in 20-40% of patients
after breast-conserving surgery, with the volume of the resected breast tissue being the major determinant. There
is clear evidence for the efficacy of ultrasonography in the resection of nonpalpable tumours. Surgical resection of
palpable breast cancer is performed with guidance by intra-operative palpation. These palpation-guided excisions
often result in an unnecessarily wide resection of adjacent healthy breast tissue, while the rate of tumour-involved
resection margins is still high. It is hypothesised that the use of intra-operative ultrasonography in the excision of
palpable breast cancer will improve the ability to spare healthy breast tissue while maintaining or even improving
the oncological margin status. The aim of this study is to compare ultrasound-guided surgery for palpable tumours
with the standard palpation-guided surgery in terms of the extent of healthy breast tissue resection, the
percentage of tumour-free margins, cosmetic outcomes and quality of life.
Methods/design: In this prospective multicentre randomised controlled clinical trial, 120 women who have been
diagnosed with palpable early-stage (T1-2N0-1) primary invasive breast cancer and deemed suitable for breast-
conserving surgery will be randomised between ultrasound-guided surgery and palpation-guided surgery. With this
sample size, an expected 20% reduction of resected breast tissue and an 18% difference in tumour-free margins
can be detected with a power of 80%. Secondary endpoints include cosmetic outcomes and quality of life. The
rationale, study design and planned analyses are described.
Conclusion: The COBALT trial is a prospective, multicentre, randomised controlled study to assess the efficacy of
ultrasound-guided breast-conserving surgery in patients with palpable early-stage primary invasive breast cancer in
terms of the sparing of breast tissue, oncological margin status, cosmetic outcomes and quality of life.
Trial Registration Number: Netherlands Trial Register (NTR): NTR2579
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Background
Breast cancer is the most common cancer among women
in the western world. It affects women of all ages and the
lifetime risk of developing invasive breast cancer is
12-13%. The 5-year disease-free survival rate for node-
negative breast cancer, however, is excellent (98%). Breast
cancer surgery has changed dramatically over the past
few decades. Breast-conserving therapy (BCT) was intro-
duced in the 1970s and refers to the surgical removal of
the breast tumour in all cases followed by radiotherapy
to eradicate residual tumour cells. The introduction of
the sentinel node procedure for nodal staging has
avoided the morbidity of axillary lymph node dissection
in the majority of patients. Several trials demonstrated
comparable results with regard to disease-free and overall
survival between mastectomy and BCT combined with
radiotherapy, and the latter has become the standard of
care for early-stage breast cancer. According to national
guidelines, 75% of breast cancer patients are suitable for
BCT. The main advantage of BCT over mastectomy is
preservation of the breast with improved cosmetic out-
comes [1-5].
Breast cancer and its treatment have many adverse
side-effects, which may be both physical and psychologi-
cal. Psychological distress is common in the breast cancer
population and affects approximately 30% of patients.
Fear of disease recurrence, concerns about future health
and interruption of life plans often lead to anxiety and
depression.
The cosmetic result is also a major determinant of psy-
chological distress. Cosmetic outcome of the breast has a
large impact on body image, and studies have shown that
women with poor cosmetic outcomes as determined by
pronounced breast asymmetry and skin alterations are
impaired in their self-esteem, feelings of sexuality and
quality of life. Furthermore, these women are more likely
to feel stigmatised and have more symptoms of depres-
sion. Focusing on the best achievable cosmetic result will
lead to a decrease in psychological distress [6-9].
Although BCT is considered the least invasive surgical
method for treatment of breast cancer, cosmetic out-
comes vary widely. Studies have reported satisfactory cos-
metic results in only 60-80% of patients, with cosmetic
failure rates up to 40%. Factors determining cosmetic
outcome after BCT include the volume of resected breast
tissue, the amount of radiotherapy, the site of the tumour
in the breast, the type of incision and postoperative com-
plications such as wound infection. Overall, a large
volume of resected breast tissue is the major determinant
of a poor cosmetic outcome. Regardless of the size of the
breast, excision volumes exceeding 85 cm3 result in a
50% rate of cosmetic failures, whereas smaller excision
volumes result in only a 22% rate of cosmetic failures.
Therefore, surgeons should excise the tumour with only
a small volume of surrounding breast tissue [10-15].
As a practical and reasonable guideline during surgery,
the aim is to achieve a safe and cosmetically acceptable
resection margin of 5-10 mm. It should be noted that
the size of the tumour-free resection margin (> 1 mm)
is unrelated to local recurrence or overall survival.
Higher risks of local recurrence have been shown only
with evident involvement of the tumour on the inked
resection margins. Therefore, there is no need to excise
a tumour with a large volume of adjacent breast tissue.
This is also stated by the Dutch national guidelines.
Accurate excision leads to a smaller and more precise
volume of surrounding breast tissue removal without
compromising the minimal tumour-free margin [16-19].
In daily practice, the succes of the removal of palpable
breast cancer is based on pre-operative imaging techni-
ques and the experience of the surgeon. The surgeon is
guided by intra-operative palpation without objective
imaging during the surgery. The primary aim of the
procedure is to achieve tumour-free resection margins
and to prevent local recurrence; a secondary aim is a
satisfactory cosmetic outcome. Avoiding inadequate
resection margins and subsequent re-excision results in
an unnecessarily wide resection of adjacent healthy
breast tissue. Indeed, our recent large retrospective mul-
ticentre study demonstrated that during routine breast-
conserving surgery, an excessive volume of breast tissue
is excised in the majority of patients. The study partici-
pants (n = 726) underwent breast-conserving surgery in
four hospitals in our region for invasive breast cancer in
three consecutive years. The volumes of the excised
specimens were calculated using histopathological
reports. It was shown that in 33.6% (244/726) of the
patients, the excised tissue volume exceeded 85 cm3,
i.e., deteriorating the cosmetic outcome. In this group,
98.8% (241/244) had presented with an excision that
exceeded the optimal resection volume (= the tumour
volume plus a 1 cm margin of tumour-free breast tis-
sue). In fact, in 54.9% (134/244) of these patients the
tumour stage was T1 and a maximum resection volume
of 33.51 cm3 would have been sufficient (optimal resec-
tion volume for a tumour size of 2 cm and an added
1 cm margin of healthy breast tissue). Also, in most
cases presenting with a tumour-free margin, the malig-
nant lesion was located eccentrically in the excision
volume, close to the nearest margin (Figure 1). Remark-
ably, the rate of focally positive or positive margins was
higher for the palpable tumours than for the nonpalp-
able tumours (22.5% and 17.4%, respectively; P = 0.13)
[20]. This might be caused by the lack of three-dimen-
sional orientation with intra-operative visualisation in
the excision of palpable tumours.
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An easily available and feasible method to improve the
amount of healthy breast tissue spared while ensuring
tumour-free resection margins is intra-operative ultraso-
nography (US). US-guided surgery (USS) enables the
surgeon to visualise the tumour during excision. Earlier
studies have clearly shown the efficacy of USS for non-
palpable tumours. Rahusen et al. reported that USS, in
which an experienced radiologist perfomed US, is super-
ior to wire-guided surgery with respect to tumour-free
resection margins (89% and 55% of cases, respectively).
Snider et al. also showed an excellent rate of tumour-
free resection margins using USS (82%) with a smaller
volume of healthy breast tissue resection compared to
wire-guided surgery (62.2 cm3 and 81.1 cm3, respec-
tively) [21-26]. Our retrospective multicentre study
showed that USS for nonpalpable invasive breast cancer
was more accurate than wire-localisation and Radio
Occult Lesion Localisation (ROLL)-guided surgery
because it optimised the surgeon’s ability to obtain ade-
quate margins (3.7%, 21.3%, and 25% tumour-involved
margins, respectively, (P < 0.05). Intra-operative ultraso-
nography for nonpalpable tumours results in a dramati-
cally lower rate of tumour-involved resection margins
than palpation-guided surgery for palpable tumours
(3.7% and 22.5%, respectively, (P < 0.05); unpublished
data) [27]. To the best of our knowledge, only one
study, by Moore et al., has evaluated the use of USS for
treatment of palpable invasive ductal breast cancer. One
group of patients received USS, and the other group
underwent surgery without an imaging technique. The
breast tissue spared and margin status were both
improved with US [28].
In general, all palpable breast masses are visible by
US. Given that the efficacy of USS has already been
shown for nonpalpable tumours, we hypothesise that
USS will also be useful for palpable tumours with
regard to improving the amount of healthy breast tissue
spared, cosmetic outcomes and quality of life while still




This study will be a multicentre prospective randomised
clinical trial. Eligible patients will be randomised for
either ultrasound-guided surgery (USS) or palpation-
guided surgery (PGS).
Subjects and patient selection
One hundred and twenty patients will be recruited over a
period of six months at a university medical center and
several medium to large hospitals in the Netherlands. All
women aged 25-75 yrs who are diagnosed with palpable
early-stage (T1-2N0-1) invasive breast cancer in the trial
centres will be invited to participate in this study. Breast
cancer will be diagnosed with physical examination,
mammography (2R) and US, and occasionally MRI of the
breast and axilla. The diagnosis of invasive (ductal or lob-
ular) breast cancer will be established with image-guided
core needle biopsy or cytological puncture. All patients
will be discussed in a multidisciplinary team, and suitable
for BCT according to national guidelines. Participants
will not have a history of prior mammary surgery of the
affected breast, radiation therapy or neo-adjuvant ther-
apy. Participants will have ASA Classification I-III and
will be well-informed having signed an informed consent
form.
Figure 1 Specimen with eccentric tumour localisation.
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Full ethical approval is obtained for this study from the
Investigational Review Board of the VU University Medi-
cal Centre, including the Medical Ethical Review Board.
Study procedures
Pre-operative
Prior to surgery, patients will be informed about this trial
by both written and oral explanations. Informed consent
will be obtained. Subsequently, the patients will complete
the quality of life questionnaire, EORTC QLQ-C30/-
BR23. The principal investigator will randomly assign the
participants to either of the two treatment modalities by
using a digital randomisation program. Group I will
undergo PGS and group II USS. Stratification by institute
will be performed to ensure balanced allocation between
the two treatment modalities in each institution.
Surgery
Surgery will be performed under general anaesthesia by
dedicated oncological breast surgeons or by surgical resi-
dents under their close supervision. The surgery will start
with the axillary procedure. In clinically node-negative
patients surgery of the axilla consists of a single sentinel
node procedure. For the sentinel node procedure, a triple
method will be used, consisting of combined lymphoscin-
tigraphy (Tc99m colloidal albumin [Nanocoll®]), Patent
Blue V® (Guerbet, Aulnay-Sous Bois, France) dye injec-
tion, and gamma probe detection [2]. In some institu-
tions, the sentinel node is sent for frozen section study,
and if metastases are diagnosed, axillary lymph node dis-
section is performed during the same procedure. Node-
positive patients who are pre-operatively confirmed by
US-guided cytological puncture will undergo an axillary
lymph node dissection. Axillary lymph node dissection is
a routine procedure, consisting of a classic level I and II
dissection. After the axillary procedure, surgery of the
breast is performed. The aim in both the USS-group and
the PGS-group will be to obtain a rim of 1 cm of healthy
adjacent breast tissue around the malignant breast lesion.
Palpation-guided surgery
In the PGS group, tumour excision will be guided by the
palpation of the surgeon in the standard manner. The
index finger will be used to palpate the mass, retract it
and guide the dissection. In this procedure, the ade-
quacy of the resection is based on the experience of the
surgeon without objective imaging during surgery.
Ultrasound-guided surgery
In the USS group, tumour excision will be performed by
the surgeon with US guidance in collaboration with an
experienced radiologist. Prior to surgery, the surgeon will
carry out an US of the lesion under direct supervision of
the radiologist. During the surgery, the radiologist will be
present either in the operating theatre or in the radiology
department. The surgical procedure will start with the
standard sentinel node procedure, after which the
US-guided lumpectomy will be performed. USS will be
performed using a THI 14-MHz US probe (Toshiba
Viamo portable ultrasound system, Japan). The probe is
coupled to a mobile US unit and covered with a sterile
sheath that enables it to be used in the surgical wound.
The lesion will be carefully localised in the breast by pal-
pation and US imaging (Figure 2). The localisation of the
lesion will be compared to the pre-operative images. The
breast tissue will be positioned in such a way that the
lesion is located as close to the skin surface as possible,
and the breast will be fixed in that position throughout the
procedure by hand or using tape. The tumour size, lesion-
to-skin distance and lesion-to-fascia distance will be mea-
sured in millimetres by US. The localisation of the tumour
will be precisely marked on the skin, and the incision will
be made. After the incision, the skin over the lesion will be
dissected from the subcutaneous tissue, and the US probe
will be positioned in the wound to reassess the position of
the lesion. Also, the index finger will be used to palpate
the mass, retract it and guide the dissection. Dissection is
continued posteriorly in the plane between the breast and
the pectoral fascia. To achieve adequate margins, US will
be applied repeatedly in the wound from different angles
while continuously monitoring the location and depth of
the tumour (Figure 3, 4). Subsequently, a spherical lump
of breast tissue will be excised. It is recommended to place
a “pool suture” around the tumour under US guidance to
facilitate the excision. After completion of the excision,
the specimen will be scanned ex vivo by US to assess the
completeness of the excision (Figure 4, 5).
The orientation of the specimen will be preserved with
marking sutures such that positive resection margins
can be identified and re-excised if necessary. Haemosta-
sis will be obtained, and drains will not be used. If
requested, titanium clips will be placed in each quadrant
to guide radiotherapy. Subcutaneous tissue will be
Figure 2 Tumour localising by ultrasound imaging.
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closed with dissolvable stitches, and the skin will be
closed with stitches or staples.
Outcome parameters (Table 1)
Perioperative parameters
The experience of the surgical residents, complications,
the duration of procedure (i.e. time from the incision to
wound closure; time needed for the axillary surgery is
excluded) and costs of the procedure are registered.
After excision the volume of the specimen will be
measured in the operating room by fluid displacement.
The specimen will be submerged in an Erlenmeyer flask
filled with normal saline at 37176;C. The volume of fluid
displaced equals the volume of the specimen. If re-exci-
sion is performed during the surgery, the volume of the
reexcised specimen will be calculated separately and
subsequently added to the originally excised specimen.
Figure 3 Ultrasound image on screen.
Figure 4 The ultrasound is applied repeatedly in the wound.
Figure 5 After excision, completeness of the specimen is
checked by ultrasonography.





Pre-operative Experience of the surgeon
Complications
Duration of the procedure
Cost of the procedure
Type of surgery in the axilla (SN or
ALND)
Adequate margins based on US ex
vivo
Specimen volume (fluid displacement
Histological Surgical specimen volume
Tumour volume (diameter) within the
specimen
Margin status
Shortest distance to the nearest
resection margin
Adjuvant therapy Radiotherapy (dose, boost)
Chemotherapy
Hormonal therapy
Two weeks post-operatively (Wound) complications
Three and six months post-
operatively
Cosmetic outcome measurements
Quality of life (questionnaires)
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Pathology
This study would not influence current pathological
examination.
After the placement of wire markers on the fresh speci-
men, the specimen is sent together with the sentinel node
immediately to the pathologist. The pathological examina-
tion of the surgical specimen and sentinel node is as follows:
The three dimensions of the surgical specimen are
measured macroscopically. Specimens will be carefully
inked and cut in 4-mm slices. Subsequently, the tumour
diameter, the site of the tumour in the surgical speci-
men, the margin status and the smallest distance to the
tumour-free resection margin will be measured (mm).
The margin status and the smallest distance to the
tumour-free resection margin will be measured more
precisely using microscopy (mm), and finally, tumour
characteristics (e.g. tumour differentiation, receptor sta-
tus) will be recorded. The three dimensions of the senti-
nel node are measured macroscopically. Lymph nodes
measuring < 5 mm are examined in toto, nodes measur-
ing > 5 mm are cut. Microscopically the presence and
size of metastasis are defined (mm).
Calculations
The ratio of the resected volume to the optimal resected
volume can be calculated from the diameter of the
tumour and the three dimensions of the specimen.
Three assumptions are made:
1) the tumour is spherical (using the radius (= ½
diameter),
2) in an optimal resection volume, a margin of 1 cm is
excised around the tumour and
3) the excised specimen is ellipsoid.
The volume of the excised specimen will be measured
during surgery by fluid displacement and the histo-
pathological ellipsoid calculation will serve as a control.
- The volume of the tumour will be calculated by 4/
3πr 3.
- The optimal volume required for excision will be
calculated by adding a resection margin of 1 cm to
the lesion radius and converting this value into a
spherical volume using the formula 4/3π(r + 1 cm) 3.
- The volume of the surgical specimen will be calcu-
lated using the formula 4/3πa b c (with a, b and c as
given in the pathology report). The specimen volume
will be compared with the optimal excision volume,
resulting in a ratio (Figure 6) [29].
Postoperative
This study would not influence current postoperative
treatment.
The current postoperative treatment is as follows:
Within two weeks after surgery, patients visit the out-
patient clinic. Pathological results and further treatment
(with multidisciplinary approach) are explained in detail.
Complications are registered and treated, with special
attention given to wound healing.
Approximately six weeks after surgery, all patients
receive radiotherapy of the affected breast. Patients
younger than 50 years old are treated with whole-
breast irradiation (50 Gy in 25 fractions) including a
simultaneously integrated boost (SIB), for a total dose
of 68,75 Gy. Patients over 50 years old receive 40 Gy
in 15 fractions with a SIB, for a total dose of 50,25 Gy.
Radiotherapy strategies may vary slightly according to
institutional guidelines.
If necessary, a medical oncologist is consulted for
the administration of systemic therapy. Adjuvant ther-
apy is administered according to national guidelines.
When multiple axillary lymph node metastases are
diagnosed, patients will receive adjuvant therapy prior
to radiotherapy.
Cosmetic Analysis
During the follow-up visits three and six months after
surgery, the cosmetic outcome will be evaluated. Stan-
dard 4-point view digital photographs, including the
suprasternal notch, will be taken. These photographs
will be scored by a panel consisting of six persons
(including both professionals and non-professionals).
The items scored will be the overall result, the appear-
ance of the surgical scar, breast size, breast shape, nipple
position and the shape of areola. The treated breast will
be compared to the untreated breast, using the 4-point
Lickert scale. Objective cosmetic analysis will be per-
formed with the Breast Retraction Assessment (BRA) or
comparable objective software. BRA values are calcu-
lated using measurements from the frontal view photo-
graphs and quantity the amount of retraction of the
treated breast compared to the healthy contralateral
breast by measuring nipple displacement. A large BRA
value corresponds to increased asymmetry between the
breasts and to poor cosmetic results (Figure 7). Subse-
quently, the patients’ opinions concerning cosmetic out-
come will be assessed using patient self-evaluation.
Long-term follow-up (3 yrs) will probably be studied in
a future research project.
Figure 6 Comparing the specimen volume with the optimal
excision volume.
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Quality of Life questionnaire
The EORTC QLQ-C30/-BR23 questionnaire will be
completed by the patient prior to surgery and during
follow-up visits three and six months after surgery.
Using a personalised interview three and six months
after surgery, patients’ feelings concerning the cosmetic
results of their breasts will be assessed more specifically.
Results will be analysed over time.
Follow-up
Oncological follow-up will continue according to
national guidelines (every three months for the first two
years). One year after surgery, follow-up will include no
study issues. If the results of this study are promising,
long-term results will be analysed (3 yrs of follow-up).
Sample size calculation
The sample size was calculated based on the primary
endpoint: volume of resected breast tissue. Previous
studies have shown that excision volumes exceeding
85 cm3 result in significantly higher cosmetic failure
rates. In our recent retrospective multicentre study it
was found that in 33.9% (244/726) of the patients the
excision volumes exceeded 85 cm3. In 98.8% (241/244)
of these patients, the CRR was > 1.0, implying that
excess tissue was excised [20]. It can therefore be con-
cluded that, in 33.2% (241/726) of all patients, excessive
tissue resection resulted in impairment of the cosmetic
outcome. Assuming that this excessive resection can be
avoided with US-guided surgery, it is expected that only
10% of women will have excessive breast tissue resection
(a ratio of > 1.0) that results in a worse cosmetic out-
come (resection volume > 85 cm3). Therefore, we
assume a difference in resected volume of 22.3% in
favour of the US group. With a statistical power of 80%
to detect this 22.3% improvement as significant (P <
0.05), we will require 57 patients in the palpation group
and 57 patients in the US group. The margin status is
currently involved in 22.5% of palpable breast tumour
excisions. To improve this rate to 5%, we will require 60
patients in the palpation group and 60 patients in the
US group. Therefore, the target sample size will be 120
patients.
Timeline
The inclusion period will run from October 2010 to July
2011. The EORTC QLQ-C30/-BR23 questionnaire will
be completed by the patient prior to surgery. Surgery
will be scheduled 1-2 weeks after diagnosis. During a
follow-up visit to the outpatient clinic, usually 1-2 weeks
after discharge, complications will be recorded and trea-
ted. Three and six months after surgery, information
will be collected from each patient concerning the cos-
metic outcome and quality of life, and photographs will
be taken. Patients can withdraw from the study at any
time during the study period.
Statistical analysis
Descriptive statistical methods will be applied. Statistical
software (i.e. SPSS 15.0.) will be used for analysis. The
95% confidence intervals of the differences between the
two groups will be calculated. The Chi-square test will
be used for comparisons of dichotomous variables. The
Students’ t-test will be used, where appropriate, for
comparisons of continuous variables. The Fisher’s exact
test will be performed where applicable. Multiple regres-
sion analysis will be used for comparisons of indepen-
dent variables. The patient, tumour and treatment
related differences will be calculated for the two treat-
ment strategies.
An interim analysis will be performed after the inclu-
sion of 60 patients (30 patients in each group). The final
data analysis will be performed after the surgeries of the
total of all 120 patients are completed. Definitive results
are expected in December 2011.
Discussion and Conclusion
The goals of breast-conserving surgery are to obtain
adequate margins and good cosmetic results. Both goals
are poorly defined, and there is no universal acceptable
standard. According to Dutch national guidelines, a
negative margin is defined as a margin of ≥ 1 mm of
normal tissue intervening between the tumour and the
edge of the specimen. Resections are described as focally
involved when cancer cells invade the resection margin
Figure 7 Breast Retraction Assessment.
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in a maximum of two microscopic slides or when mar-
gins include < 1 mm of normal tissue. The margins are
described as involved or positive when microscopic can-
cer cells are situated on the inked resection border. It
has been well-established that the status of the margin
affects the local recurrence rate. Therefore, re-excision
is indicated for involved margins. Vrieling et al. showed
that patients with focally involved margins have lower
rates of recurrence when treated with a higher radiation
boost dose, equal to patients with adequate margins.
Therefore, a higher boost dose is given to patients with
focally involved margins without further surgery. This
has been confirmed by national guidelines [15-19].
To analyse cosmetic outcomes, frequently used subjec-
tive methods are patient self-evaluation and panel eva-
luation. Patient self-evaluation is a valuable method as
the patient’s opinion is of great importance; however,
patients tend to report consistently better scores than
professionals. Panel-evaluation, consisting of a panel of
six professionals and non-professionals, has proven to
be the most reliable subjective method. The panel evalu-
ates 4-point view pictures of the breasts [8,13]. Breast
Retraction Assessment (BRA) is a well-validated and fre-
quently used objective method to evaluate breast asym-
metry. The BRA is reliable and minimally time-
consuming; however, it is only correlated moderately for
tumours located in the lower quadrant, and skin
changes (e.g. disturbing scars or telangiectasias) are not
taken into account. In the framework of the EORTC
trial, Vrieling et al. compared these different methods of
cosmetic outcome assessment. The BRA is recom-
mended for comparing the cosmetic outcomes between
two different approaches to BCT and for analysing cos-
metic changes over time. The panel evaluation gives the
best measure of the overall cosmetic result. Therefore,
in order to assess cosmetic outcomes, the most appro-
priate method is to combine the panel evaluation and
the BRA into an overall score. Patient self-evaluation is
necessary with regard to quality of life [30,31].
The excision of nonpalpable breast cancer can be per-
formed with guidance from several tools. The wire-loca-
lisation (WL) is still the gold standard. The WL
procedure is technically demanding and depends on
both the wire placement by the radiologist and on the
experience and three-dimensional orientation of the sur-
geon. The insertion of the wire can be uncomfortable
for the patient; Furthermore, there is a risk of wire
migration between the time of insertion and the begin-
ning of the surgery. Other less frequently used techni-
ques are emerging, including the use of radioactive seed
implants, an electrosurgical loop device and Radio-
guided Occult Lesion Localisation (ROLL), which uses a
radioactive pharmaceutical that is injected into the
tumour pre-operatively. A gamma probe is used to
guide the surgical resection. A drawback is that these
guidance tools are invasive. Currently, these techniques
are being validated [32-34]. Intra-operative ultrasonogra-
phy (US) was introduced in 1988 as an easily available
and patient-comfortable method of excising a tumour
under direct vision. Using intra-operative US, surgeons
can localise and guide the excision of non-palpable
lesions, without the need for additional interventions
before surgery. After specimen removal, the US is valu-
able to confirm excision and check margin clearance
before wound closure. However, a possible restriction is
the arrangement of a radiologist’s presence in the oper-
ating theatre. In our multicentre study wire-localisation
(WL), ROLL and USS were retrospectively compared.
USS was clearly the most effective method for the exci-
sion of nonpalpable tumours [27]. Moreover, a number
of studies such as Rahusen et al. and Snider et al. have
clearly demonstrated that intra-operative US guidance
has considerable advantages over wire-guided excision,
including reduced pre-operative stress and discomfort
for patients and decreased operating room time. Most
importantly, intra-operative US guidance resulted in
improved resection margins and smaller excision
volumes.
High-frequency US shows most lesions, and in gen-
eral, all palpable breast lesions are visible with ultraso-
nography (US). Therefore, intra-operative US is
applicable in the majority of women with a palpable
breast cancer [21-26,28,33].
Intra-operative ultrasonography will contribute to
improved cosmetic outcomes by:
1. Smaller volumes of resected breast tissue
2. Improvement of margin status
- avoiding a higher boost dose for focally
involved margins
- avoiding re-excision or even mastectomy for
involved margins
Approximately 9000 out of 13000 breast cancer
patients are diagnosed with a palpable breast cancer in
the Netherlands each year, and around 5000 patients
undergo breast-conserving surgery for a palpable
breast cancer. An improvement of cosmetic outcomes
in an estimated n = 1115 (22.3%) of all patients treated
with breast-conserving surgery can be achieved by
USS. Also, an estimated n = 875 (17.5%) less opera-
tions will be necessary after treatment by US-guided
surgery (A re-operation costs about € 7 000, -, so
eventually € 6 125 000, - might be saved by this
method each year).
In conclusion, this randomised controlled trial aims to
demonstrate the superiority of USS versus PGS for the
treatment of patients with palpable breast cancer in
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terms of the sparing of breast tissue, oncological margin
status, cosmetic outcomes and quality of life.
Abbreviations
BCT: Breast-conserving therapy; US: Ultrasonography or ultrasound; WL: Wire
localisation; ROLL: Radio-guided Occult Lesion Localisation; USS: Ultrasound-
guided surgery; PGS: Palpation-guided surgery; METc: Medical Research
Ethics Committee (MREC) (in Dutch: Medisch Ethische Toetsingscommissie
(METc)).
Acknowledgements
Written consent for publication was obtained from the participating patients.
The Dutch “Pink Ribbon” Foundation has provided funding for this trial.
The “Osinga-Kluis Foundation” has provided funding for a Toshiba Viamo
portable ultrasound system. Toshiba medical systems corporation provided
two extra Viamo portable ultrasound systems for use during the clinical trial.
Author details
1Department of Surgical Oncology, VU University Medical Centre,
Amsterdam, the Netherlands. 2Department of Surgical Oncology, Medical
Centre Alkmaar, Alkmaar, the Netherlands. 3Department of Surgical
Oncology, Kennemer Gasthuis, Haarlem, the Netherlands. 4Department of
Surgical Oncology, Rode Kruis Hospital, Beverwijk, the Netherlands.
5Department of Surgical Oncology, Waterland Hospital, Purmerend, the
Netherlands. 6Department of Surgical Oncology, Gelderse Vallei Hospital, Ede,
the Netherlands. 7Department of Radiology, VU University Medical Centre,
Amsterdam, the Netherlands. 8Department of Medical Psychology and
Medical Oncology, VU University Medical Centre, Amsterdam, the
Netherlands. 9Department of Epidemiology and Biostatistics, VU University
Medical Centre, Amsterdam, the Netherlands. 10Department of Plastic and
Reconstructive Surgery, VU University Medical Centre, Amsterdam, the
Netherlands.
Authors’ contributions
NMAK, BMZ, SM, SM, and PMPT drafted the manuscript and made
substantial contributions to the acquisition of funding. NMAK, BMZ, SM,
HWHS, HR, HV, SM, and PMPT participated in the collection of all
retrospective data. NMAK, BMZ, SM, HWHS, AMFLC, WKR, AMB, HR, PP, LW,
HV, HAHW, SM, and PMPT have made substantial contribution to the
conception and design of the study. SM, HWHS, AMFLC, WKR, AMB, HR, PP,
LW, HV, SM, and PMPT have made great efforts to be trained in the ultra-
sound guided breast surgery techniques, since they are the participating
surgeons. They are also crucial in the inclusion of patients and the collection
of all data of the randomised controlled trial. AHMTA and EB made
contribution to the conception of the study and the design of the study, in
particular for the technical part of ultrasonography. They teach the surgeons
how to use the ultrasound. ML participated in the design of the quality of
life assessment, constructed the questionnaires, and will carry out all quality
of life interviews. ESMLK participated in the design of the study and carried
out the statistical analysis, the interpretation of data and sample size
calculations. HAHW participated in the design of the cosmetic assessment,
and will conduct the panel evaluation. All authors read and approved the
submitted version of the manuscript. SM, and PMPT have given final
approval of the final version to be published.
Competing interests
The authors declare that they have no competing interests.
Received: 7 October 2010 Accepted: 16 March 2011
Published: 16 March 2011
References
1. cijfers, overleving; borst. Nederlands Kankerregistratie (NKR);, 6 2003.
2. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S:
Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of
lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998,
186:275-283.
3. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al:
Twenty-year follow-up of a randomized trial comparing total
mastectomy, lumpectomy, and lumpectomy plus irradiation for the
treatment of invasive breast cancer. N Engl J Med 2002, 347:1233-1241.
4. Rahusen FD, Pijpers R, van Diest PJ, Bleichrodt RP, Torrenga H, Meijer S: The
implementation of the sentinel node biopsy as a routine procedure for
patients with breast cancer. Surgery 2000, 128:6-12.
5. Veronesi U, Banfi A, Salvadori B, Luini A, Saccozzi R, Zucali R, et al: Breast
conservation is the treatment of choice in small breast cancer: long-
term results of a randomized trial. Eur J Cancer 1990, 26:668-670.
6. Al-Ghazal SK, Fallowfield L, Blamey RW: Does cosmetic outcome from
treatment of primary breast cancer influence psychosocial morbidity?
Eur J Surg Oncol 1999, 25:571-573.
7. Curran D, van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F,
et al: Quality of life of early-stage breast cancer patients treated with
radical mastectomy or breast-conserving procedures: results of EORTC
Trial 10801. Eur J Cancer 1998, 34:307-314.
8. Sneeuw KC, Aaronson NK, Yarnold JR, Broderick M, Regan J, Ross G, et al:
Cosmetic and functional outcomes of breast conserving treatment for
early stage breast cancer. 2. Relationship with psychosocial functioning.
Radiother Oncol 1992, 25:160-166.
9. Waljee JF, Hu ES, Ubel PA, Smith DM, Newman LA, Alderman AK: Effect of
esthetic outcome after breast-conserving surgery on psychosocial
functioning and quality of life. J Clin Oncol 2008, 26:3331-3337.
10. Al-Ghazal SK, Blamey RW, Stewart J, Morgan AA: The cosmetic outcome in
early breast cancer treated with breast conservation. Eur J Surg Oncol
1999, 25:566-570.
11. Cochrane RA, Valasiadou P, Wilson ARM, Al-Ghazal SK, Macmillan RD:
Cosmesis and satisfaction after breast-conserving surgery correlates with
the percentage of breast volume excised. Br J Surg 2003, 90:1505-1509.
12. Fabry HFJ, Zonderhuis BM, Meijer S, Berkhof J, Van Leeuwen PAM, Van der
Sijp JRM: Cosmetic outcome of breast conserving therapy after sentinel
node biopsy versus axillary lymph node dissection. Breast Cancer Res
Treat 2005, 92:157-162.
13. Sneeuw KC, Aaronson NK, Yarnold JR, Broderick M, Regan J, Ross G, et al:
Cosmetic and functional outcomes of breast conserving treatment for
early stage breast cancer. 1. Comparison of patients’ ratings, observers’
ratings, and objective assessments. Radiother Oncol 1992, 25:153-159.
14. Taylor ME, Perez CA, Halverson KJ, Kuske RR, Philpott GW, Garcia DM, et al:
Factors influencing cosmetic results after conservation therapy for
breast cancer. Int J Radiat Oncol Biol Phys 1995, 31:753-764.
15. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, et al:
The influence of patient, tumor and treatment factors on the cosmetic
results after breast-conserving therapy in the EORTC ‘boost vs. no boost’
trial. Radiother Oncol 2000, 55:219-232.
16. Kaufmann M, Morrow M, von Minckwitz G, Harris JR: Locoregional
treatment of primary breast cancer: consensus recommendations from
an International Expert Panel. Cancer 2010, 116:1184-1191.
17. Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, et al:
Positive surgical margins and ipsilateral breast tumor recurrence predict
disease-specific survival after breast-conserving therapy. Cancer 2003,
97:926-933.
18. Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, et al:
Outcome at 8 years after breast-conserving surgery and radiation
therapy for invasive breast cancer: influence of margin status and
systemic therapy on local recurrence. J Clin Oncol 2000, 18:1668-1675.
19. Singletary SE: Surgical margins in patients with early-stage breast cancer
treated with breast conservation therapy. Am J Surg 2002, 184:383-393.
20. Krekel NMA, Zonderhuis BM, Muller S, Bril H, van Slooten HJ, de Lange de
Klerk ESM, et al: Excessive resections in breast-conserving surgery: A
retrospective multicentre study. Breast J 2011, 17(5).
21. Harlow SP, Krag DN, Ames SE, Weaver DL: Intraoperative ultrasound
localization to guide surgical excision of nonpalpable breast carcinoma.
J Am Coll Surg 1999, 189:241-246.
22. Kaufman CS, Jacobson L, Bachman B, Kaufman LB: Intraoperative
ultrasonography guidance is accurate and efficient according to results
in 100 breast cancer patients. Am J Surg 2003, 186:378-382.
23. Luini A, Zurrida S, Paganelli G, Galimberti V, Sacchini V, Monti S, et al:
Comparison of radioguided excision with wire localization of occult
breast lesions. Br J Surg 1999, 86:522-525.
24. Rahusen FD, Taets van Amerongen AH, van Diest PJ, Borgstein PJ,
Bleichrodt RP, Meijer S: Ultrasound-guided lumpectomy of nonpalpable
Krekel et al. BMC Surgery 2011, 11:8
http://www.biomedcentral.com/1471-2482/11/8
Page 9 of 10
breast cancers: A feasibility study looking at the accuracy of obtained
margins. J Surg Oncol 1999, 72:72-76.
25. Rahusen FD, Bremers AJA, Fabry HFJ, van Amerongen AHMT, Boom RPA,
Meijer S: Ultrasound-guided lumpectomy of nonpalpable breast cancer
versus wire-guided resection: a randomized clinical trial. Ann Surg Oncol
2002, 9:994-998.
26. Snider HCJ, Morrison DG: Intraoperative ultrasound localization of
nonpalpable breast lesions. Ann Surg Oncol 1999, 6:308-314.
27. Krekel NMA, Zonderhuis BM, Stockmann HBAC, Schreurs WH, van der
Veen H, de Lange de Klerk ESM, et al: A comparison of three methods for
nonpalpable breast cancer excision. Eur J Surg Oncol 2011, 37:109-115.
28. Moore MM, Whitney LA, Cerilli L, Imbrie JZ, Bunch M, Simpson VB, et al:
Intraoperative ultrasound is associated with clear lumpectomy margins
for palpable infiltrating ductal breast cancer. Ann Surg 2001, 233:761-768.
29. Leijendeckers PHH, Fortuin JB, van Herwijnen F, Schwippert GA: Wiskunde,
Meetkunde; A2. Polytechnisch Zakboek Elsevier; 2010, 36-37.
30. Sacchini V, Luini A, Tana S, Lozza L, Galimberti V, Merson M, et al:
Quantitative and qualitative cosmetic evaluation after conservative
treatment for breast cancer. Eur J Cancer 1991, 27:1395-1400.
31. Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC,
et al: Validation of the methods of cosmetic assessment after breast-
conserving therapy in the EORTC “boost versus no boost” trial. EORTC
Radiotherapy and Breast Cancer Cooperative Groups. European
Organization for Research and Treatment of Cancer. Int J Radiat Oncol
Biol Phys 1999, 45:667-676.
32. Rampaul RS, Macmillan RD, Evans AJ: Intraductal injection of the breast: a
potential pitfall of radioisotope occult lesion localization. Br J Radiol 2003,
76:425-426.
33. Rampaul RS, Bagnall M, Burrell H, Pinder SE, Evans AJ, Macmillan RD:
Randomized clinical trial comparing radioisotope occult lesion
localization and wire-guided excision for biopsy of occult breast lesions.
Br J Surg 2004, 91:1575-1577.
34. van der Ploeg IMC, Hobbelink M, van den Bosch MAAJ, Mali WPT, Borel
Rinkes IHM, van Hillegersberg R: ’Radioguided occult lesion localisation’
(ROLL) for non-palpable breast lesions: a review of the relevant
literature. Eur J Surg Oncol 2008, 34:1-5.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2482/11/8/prepub
doi:10.1186/1471-2482-11-8
Cite this article as: Krekel et al.: Ultrasound-guided breast-sparing surgery
to improve cosmetic outcomes and quality of life. A prospective
multicentre randomised controlled clinical trial comparing ultrasound-
guided surgery to traditional palpation-guided surgery (COBALT trial). BMC
Surgery 2011 11:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Krekel et al. BMC Surgery 2011, 11:8
http://www.biomedcentral.com/1471-2482/11/8
Page 10 of 10
